News

The first participants were vaccinated in the study with Pfizer’s respiratory syncytial virus (RSV) investigational vaccine candidate in adults ages 60 or older.

HIV coinfection was associated with a 3.7-fold increase in the risk of non-liver-related cancer among patients with hepatitis C virus infection, a new study found.

Although the risk of contracting COVID-19 remains low post full vaccination, investigators found there was a 49% less risk with developing long COVID.

Optimizing delivery of HIV preexposure prophylaxis will take more than access to health care, according to a recent analysis of PrEP use behaviors among adults in an integrated health system.

The STOP Spillover project is aiming to prevent remerging infectious disease outbreaks.

Despite heightened cardiovascular disease (CVD) risk, too few get drugs at appropriate dose, researchers say.

JAMA study highlights more reluctance among communities of color.

It is important to go out into the local communities to educate people about PrEP as countries try to scale up with the World Health Organization’s (WHO) PrEP recommendations.

The World Health Organization (WHO) reports on a newly classified variant of interest (VOI) and information about another South African strain is made public. In the US, the Food and Drug Administration (FDA) prepares for meetings on COVID-19 booster doses.

The federal agency is advising people to not eat Fratelli Beretta brand prepackaged uncured antipasto trays.

Incidence of cholangitis with mult-drug resistant bacteria was higher among patients who regularly use proton pump inhibitors, a new study in Japan found.

The company reported its third shot induced antibody responses of more than 40 times against the Delta variant.

Montefiore Health System has a long history of treating infectious disease, and with the current pandemic and other emerging pathogens, they remain vigilant to potential outbreaks.

Purified nisin is effective at killing Clostridioides difficile, a recent ex vivo study demonstrated, opening up the potential to use the bacteriocin as a treatment.

In the latest article from SIDP, here is a look at therapy options addressing this emerging clinical challenge.

Global use of HIV pre-exposure prophylaxis has risen as more countries have adopted World Health Organization recommendations.

The European Council decides to remove the United States from the list of safe countries for non-essential travelers to come into the European Union (EU).

New Imbokodo findings show a 4-dose regimen was only about 25% effective in preventing HIV in at-risk women, hindering progress for the vaccine.

Annals of Internal Medicine study shows move away from hydroxychloroquine to more proven therapies.

The adoption of numerous HIV prevention measures was associated with an 80% drop in the number of HIV diagnoses, a study evaluating the success of 56 Dean Street in London found.

Persons living with HIV are susceptible to TB and also appear at increased risk for infecting strains acquiring rifampicin-resistance.

New Zealand is reporting the first death of a person shortly after the vaccine was administered.

AstraZeneca’s combination of 2 long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 significantly.

In a head-to-head randomized controlled trial, 30% of outpatients who received convalescent plasma had disease progression, compared to 31.9% of patients who received placebo.

Public health guidance differed between countries in part because of a lack of relevant scientific evidence, resource limitations, and differing strategies, according to a new report.

The deaths occurred this month in Japan, and investigations into the deaths and the vaccine batches are ongoing.

A study from the United Kingdom shows the newer variant led to an increase in severe infections in a mostly unvaccinated population.

Here is a glimpse of the surge in incidence rates of the variant as it began to take hold in Mesa County, Colorado.

The Centers for Disease Control and Prevention (CDC) released data this week that showed greater breakthrough infections in a large study mainly compiled before the emergence of Delta as the predominant variant in the US.

The National Institutes of Health (NIH) announces single injection of monoclonal antibody against the Plasmodium mosquito-borne parasite prevented malaria throughout 9 month phase 1 trial.